A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)

Influenza Clinical Trial

Official title:

A Randomized, Open-label (Part A) or Double-blind (Part B), Active-controlled (Part B) Phase I/IIa Study to Investigate the Safety, Tolerability, and Immunogenicity of GC3110A (Quadrivalent Influenza Vaccine)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02121782
• Other study ID #: GC3110A_P1/2a
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: April 22, 2014
• Last updated: August 12, 2014
• Start date: May 2014
• Est. completion date: June 2014

Study information

• Verified date: August 2014
• Source: Green Cross Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Ministry of Food and Drug Safety
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether GC3110A (a QIV) is effective compared to GC Flu Pre-filled Syringe Inj. (a marketed TIV) after single intramuscular administration in Korean healthy adults.

The comparator, GC Flu pre-filled syringe inj. is a trivalent influenza vaccine (TIV) including viruses representing 3 influenza strains (one A/HIN1, one A/H3N2, and one B). However, two antigenically distinct lineages of influenza B (Victoria and Yamagata) co-circulate annually in the United States. Predicting which lineage of influenza B will predominate during a season is challenging, and cross-protection by immunization against the other lineage is expected to be low. One proposed alternative is to produce a quadrivalent influenza vaccine (QIV) including an influenza B virus from each of the two circulating lineages. GC3110A is a new quadrivalent influenza vaccine (QIV), which contains all of 4 vaccine components WHO recommends for use in the 2013-14 influenza season (northern hemisphere winter) and includes two influenza B viruses. GC3110A is expected to show the additional public health benefit compared with traditional TIV.

Description:

This study is the first in human trial of GC3110A and is designed as an adaptive Phase I/IIa to ensure participants protection. Part A is an open-label and single arm study in 9 healthy volunteers. Data and Safety Monitoring Board (DSMB) will review the solicited/unsolicited adverse events conditionally if any toxicity of Grade 3 or 4 has been reported during 7 days after vaccination. Part B is a randomized (2:1), double-blind, active controlled study and a total of 75 volunteers will participate in this part. Adverse events assessment will be done according to the 'Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials'.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Given written informed consent

• Healthy Korean adults (age: between over 19 and under 65)

• Korean adults who agree with 21 days follow up after vaccination and good compliance to study procedures

• Those who are able to comply with the requirements for the study

Exclusion Criteria:

• Inability in written/verbal communication

• Subjects who have participated in other interventional study within 30 days

• Alcohol or drug abuse within 6 months

• Heavy drinkers or subjects who do not agree to stop drinking for 3 days before vaccination and other 3 days after vaccination

• Who got the treatment of psychotropic drugs and narcotic analgesic drugs within 6 months of enrollment

• Hypersensitivity with drug or active ingredient

• Disorders in immune function

• History of Guillain-Barré syndrome

• Disease/medications which are likely to cause any severe bleeding

• Active infection or experience of fever (>38.0 ?) within 72 hours following vaccination

• Oral temperature >38.0 ? at the vaccination day

• Erythema, tattoo, injury at shoulder (vaccination site)

• Hypersensitivity with egg, chicken, or any of the vaccine components, or Neomycin, Gentamicin

• Influenza vaccination within 6months

• Any vaccination within 30 days

• Concomitant medications/therapy such as immunosuppressants or immune modifying drugs, systemic corticosteroids, immunoglobulins, blood or blood- derived products, or anti-cancer chemotherapy or radiation therapy within3 months

• Pregnant or breast-feeding women

• Clinically significant underlying diseases or medical history at investigator's discretion

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• Quadrivalent influenza vaccine
GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
• Trivalent influenza vaccine
GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1

Locations

Country	Name	City	State
Korea, Republic of	Korea University Guro Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Green Cross Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Solicited adverse events following vaccination	Solicited injection site reactions: Pain, Tenderness, Erythema, Redness, Induration, and Swelling; Solicited systemic reactions: Fever, Sweating, Chill, Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, arthralgia.	Day 1 up to 7 Days post vaccination	Yes
Primary	Unsolicited adverse events following vaccination	It can be estimated by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials	Day 1 up to 22 Days post vaccination	Yes
Primary	Seroconversion rate of HI (Hemagglutination Inhibition) antibody for each strain		Day 22 post vaccination	No
Primary	Seroprotection rate of HI (Hemagglutination Inhibition) antibody for each strain		Day 22 post vaccination	No
Secondary	Abnormalities in physical examination, vital signs, and/or clinical laboratory tests		Day 22 post vaccination	Yes
Secondary	GMT(geometric mean titers) for each strain		Day 22 post vaccination	No